Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jackson Laboratory Resource Report Resource Website 10000+ mentions |
Jackson Laboratory (RRID:SCR_004633) | JAX | institution | An independent, nonprofit organization focused on mammalian genetics research to advance human health. Their mission is to discover the genetic basis for preventing, treating, and curing human disease, and to enable research for the global biomedical community. Jackson Laboratory breeds and manages colonies of mice as resources for other research institutions and laboratories, along with providing software and techniques. Jackson Lab also conducts genetic research and provides educational material for various educational levels. | genomic, disease, mouse model, human disease, biomaterial manufacture |
is listed by: One Mind Biospecimen Bank Listing is affiliated with: Integrative Human Microbiome Project is related to: ScienceExchange is related to: Federation of International Mouse Resources is related to: MGI strains is related to: One Mind Biospecimen Bank Listing is related to: Beta Cell Biology Consortium is related to: Mouse Mutagenesis Center for Developmental Defects is related to: GenomeMUSter is parent organization of: Mouse Models For Alzheimer's Disease Research is parent organization of: Type 1 Diabetes Resource is parent organization of: MouseCyc is parent organization of: Special Mouse Strains Resource is parent organization of: Gene Weaver is parent organization of: Mouse Phenome Database (MPD) is parent organization of: Jackson Laboratory Cytogenetic Models Resource is parent organization of: Parkinson's Disease Mouse Model Resource is parent organization of: Eye mutant resource - The Jackson Laboratory is parent organization of: Brainbow mouse resource at Jackson Labs is parent organization of: Short Course on the Genetics of Addiction is parent organization of: JAX Cre Repository is parent organization of: Donate a strain to The Jackson Laboratory Repository is parent organization of: Jackson Laboratory Neurobiology is parent organization of: QTL Archive is parent organization of: Mouse Genome Informatics: The Gene Ontology Project is parent organization of: Mouse Genome Informatics (MGI) is parent organization of: Mouse Tumor Biology Database is parent organization of: Gene Expression Database is parent organization of: The Jackson Laboratory Hearing Research Program is parent organization of: JAX Mice: Neural Tube Defects is parent organization of: JAX Neuroscience Mutagenesis Facility is parent organization of: Induced Mutant Resource is parent organization of: Mouse Mutant Resource is parent organization of: Mouse Genome Database is parent organization of: Mutant Mouse Resource and Research Center is parent organization of: eMouseAtlas is parent organization of: GBRS is parent organization of: Jackson Laboratory Scientific Instrument Services Core Facility provides: Knockout Mouse Project Repository |
Types 1 diabetes, Type 2 diabetes, Diabetes, Cardiovascular diseases, Metabolic disease, Cancer, Rare disease, Alzheimer's disease, Demantia | Available to the research community, Available to the educational community | nlx_63162, ISNI: 0000 0004 0374 0039, grid.249880.f, Crossref funder ID: 100005946 | https://ror.org/021sy4w91 | SCR_004633 | JAX Lab, Jackson Lab | 2026-08-01 12:02:43 | 14831 | |||||
|
Juvenile Diabetes Research Foundation Resource Report Resource Website 50+ mentions |
Juvenile Diabetes Research Foundation (RRID:SCR_001522) | JDRF | institution | Global funder of type 1 diabetes (T1D) research that aims to progressively remove the impact of T1D from people's lives until a world without T1D is achieved. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. More than 80 percent of JDRF's expenditures directly support research and research-related education. In 2012 Forbes magazine named JDRF one of its five All-Star charities, citing the organization's efficiency and effectiveness. The organization awards research grants for laboratory and clinical investigations and sponsors a variety of career development and research training programs for new and established investigators. JDRF also sponsors international workshops and conferences for biomedical researchers. Individual chapters offer support groups and other activities for families affected by diabetes. | treatment, prevention, cure, research, education |
is listed by: NIDDK Information Network (dkNET) is affiliated with: Helmsley Cellular Research Hub is related to: JDRF Artificial Pancreas Project Consortium is related to: Kidney Health Initiative |
Type 1 diaberes, Diabetes | Free, Freely available | grid.429307.b, nlx_152841, Crossref funder ID: 100008871, Wikidata: Q6107958, ISNI: 0000 0004 0575 6413 | https://ror.org/00vqxjy61 | SCR_001522 | JDRF International, Juvenile Diabetes Research Foundation International | 2026-08-01 12:01:53 | 64 | |||||
|
Jaeb Center for Health Research Resource Report Resource Website 1+ mentions |
Jaeb Center for Health Research (RRID:SCR_001513) | JCHR | institution | Freestanding, nonprofit coordinating center for multi-center clinical trials and epidemiologic research that focus on projects involving eye disorders or type 1 diabetes. | epidemiologic research, epidemiology, clinical, disease, clinical trial, eye |
is parent organization of: Diabetes Research in Children Network is parent organization of: Diabetic Retinopathy Clinical Research Network is parent organization of: JDRF Artificial Pancreas Project Consortium |
Type 1 diabetes, Multiple sclerosis, Eye disorder, Diabetes | Free, Freely available | ISNI: 0000 0004 0586 473X, nlx_152815, grid.414912.b | https://ror.org/04ezjnq35 | SCR_001513 | 2026-08-01 12:01:53 | 4 | ||||||
|
TRIGR Resource Report Resource Website 1+ mentions |
TRIGR (RRID:SCR_001550) | TRIGR | clinical trial | International, randomized, double-blinded trial to determine whether weaning to a casein hydrolysate formula during the first 6-8 months of life in place of cow milk based formula reduces the incidence of autoimmunity and type 1 diabetes in genetically susceptible newborn infants. 2160 eligible infants were randomized to test or control formulas when mothers decide to wean from exclusive breastfeeding. The participants will be monitored up to the age of 10 years for the appearance of diabetes-predictive autoantibodies and clinical type 1 diabetes. The TRIGR trial will determine whether delayed exposure to intact food proteins will reduce the chances of developing type 1 diabetes later in life. All babies in the study received the recommendation to breastfeed for at least the first six months of life. If a mother was unable to exclusively breastfeed before the baby was 8 months of age, her child was randomly assigned to one of two groups. One group of these babies received a trial formula based on extensively hydrolyzed protein; the other group received another trial formula containing a smaller amount of hydrolyzed protein. In the hydrolyzed formula, the big protein molecules have been split into very small fragments to provide a source of nutritional amino acids, but the fragments are likely too small to stimulate the immune system. The TRIGR trial will also be able to analyze whether exclusive breastfeeding per se can reduce the risk of the children to develop type 1 diabetes. | casein hydrolysate formula, newborn, hydrolyzed infant formula, genetically susceptible, insulin, cow's milk, infant, feeding, diet, intervention, genetic risk, bibliography, dietary intervention, wean, prevention, nutrition, nonhydrolyzed infant formula, breast feeding, infant formula |
is listed by: ClinicalTrials.gov is listed by: NIDDK Research Resources is listed by: NIDDK Information Network (dkNET) has parent organization: University of South Florida; Florida; USA |
Type 1 diabetes, Diabetes | NICHD HD040364; NICHD HD042444; NICHD HD051997; RTD programme Quality of Life and Management of Living Resources contract QLK1-2002-00372 |
PMID:21153533 PMID:17550422 |
Free, Freely available | nlx_152860 | http://trigr.epi.usf.edu/, http://clinicaltrials.gov/show/NCT00179777 | SCR_001550 | TRIGR - Trial to Reduce IDDM in the Genetically at Risk, Trial to Reduce IDDM in the Genetically at Risk, TRIGR trial | 2026-08-01 12:01:31 | 1 | |||
|
Diabetes Autoantibody Standardization Program Resource Report Resource Website 10+ mentions |
Diabetes Autoantibody Standardization Program (RRID:SCR_006929) | DASP | knowledge environment | Program that develops materials and methods to improve measurements of autoantibodies that are predictive of type 1 diabetes. These are the most sensitive and meaningful measures for predicting this disease. Historically, autoantibody measures have been variable among laboratories; therefore, this program, in collaboration with the Immunology of Diabetes Society, was established. The goals of DASP are to improve laboratory methods, evaluate laboratory performance, support the development of sensitive and specific measurement technologies, and develop reference methods. Currently, 48 key laboratories from 19 countries participate in DASP. | autoantibody, quality assurance, standardization, standard, laboratory method, laboratory performance, measurement, method |
is related to: NIDDK Information Network (dkNET) has parent organization: Centers for Disease Control and Prevention |
Type 1 diabetes, Diabetes | PMID:12716742 | nlx_152868 | http://www.idsoc.org/committees/antibody/dasphome.html | SCR_006929 | Diabetes Autoantibody Standardization Program (DASP) | 2026-08-01 12:03:24 | 14 | |||||
|
Wellcome Trust Case Control Consortium Resource Report Resource Website 100+ mentions |
Wellcome Trust Case Control Consortium (RRID:SCR_001973) | WTCCC | data or information resource | Consortium of 50 research groups across the UK to harness the power of newly-available genotyping technologies to improve our understanding of the aetiological basis of several major causes of global disease. The consortium has gathered genotype data for up to 500,000 sites of genome sequence variation (single nucleotide polymorphisms or SNPs) in samples ascertained for the disease phenotypes. Analysis of the genome-wide association data generated has lead to the identification of many SNPs and genes showing evidence of association with disease susceptibility, some of which will be followed up in future studies. In addition, the Consortium has gained important insights into the technical, analytical, methodological and biological aspects of genome-wide association analysis. The core of the study comprised an analysis of 2,000 samples from each of seven diseases (type 1 diabetes, type 2 diabetes, coronary heart disease, hypertension, bipolar disorder, rheumatoid arthritis and Crohn's disease). For each disease, the case samples have been ascertained from sites widely distributed across Great Britain, allowing us to obtain considerable efficiencies by comparing each of these case populations to a common set of 3,000 nationally-ascertained controls also from England, Scotland and Wales. These controls come from two sources: 1,500 are representative samples from the 1958 British Birth Cohort and 1,500 are blood donors recruited by the three national UK Blood Services. One of the questions that the WTCCC study has addressed relates to the relative merits of these alternative strategies for the generation of representative population cohorts. Genotyping for this main Case Control study was conducted by Affymetrix using the (commercial) Affymetrix 500K chip. As part of this study a total of 17,000 samples were typed for 500,000 SNPs. There are two additional components to the study. First, the WTCCC award is part-funding a study of host resistance to infectious diseases in African populations. The same approach has been used to type 2,000 cases of tuberculosis (TB) and 2,000 cases of malaria, as well as 2,000 shared controls. As well as addressing diseases of major global significance, and extending WTCCC coverage into the area of infectious disease, the inclusion of samples of African origin has obvious benefits with respect to methodological aspects of genome-wide association analysis. Second, the WTCCC has, for four additional diseases (autoimmune thyroid disease, breast cancer, ankylosing spondylitis, multiple sclerosis), completed an analysis of 15,000 SNPs designed to represent a large proportion of the known non-synonymous coding SNPs across the genome. This analysis has been performed at the WTSI using a custom Infinium chip (Illumina). Data release The genotypic data of the control samples (1958 British Birth Cohort and UK Blood Service) and from seven diseases analyzed in the main study are now available to qualified researchers. Summary genotype statistics for these collections are available directly from the website. Access to the individual-level genotype data and summary genotype statistics is by application to the Consortium Data Access Committee (CDAC) and approval subject to a Data Access Agreement. WTCCC2: A further round of GWA studies were funded in April 2008. These include 15 WTCCC-collaborative studies and 12 independent studies be supported totaling approximately 120,000 samples. Many of the studies represent major international collaborative networks that have together assembled large sample collections. WTCCC2 will perform genome-wide association studies in 13 disease conditions: Ankylosing spondylitis, Barrett's oesophagus and oesophageal adenocarcinoma, glaucoma, ischaemic stroke, multiple sclerosis, pre-eclampsia, Parkinson's disease, psychosis endophenotypes, psoriasis, schizophrenia, ulcerative colitis and visceral leishmaniasis. WTCCC2 will also investigate the genetics of reading and mathematics abilities in children and the pharmacogenomics of statin response. Over 60,000 samples will be analyzed using either the Affymetrix v6.0 chip or the Illumina 660K chip. The WTCCC2 will also genotype 3,000 controls each from the 1958 British Birth cohort and the UK Blood Service control group, and the 6,000 controls will be genotyped on both the Affymetrix v6.0 and Illumina 1.2M chips. WTCCC3: The Wellcome Trust has provided support for a further round of GWA studies in January 2009. These include 5 WTCCC-collaborative studies to be carried out in WTCCC3 and 5 independent studies, across a range of diseases. Many of the studies represent major international collaborative networks that have together assembled large sample collections. WTCCC3 will perform genome-wide association studies in the following 4 disease conditions: primary biliary cirrhosis, anorexia nervosa, pre-eclampsia in UK subjects, and the interactions between donor and recipient DNA related to early and late renal transplant dysfunction. The WTCCC3 will also carry out a pilot in a study of the genetics of host control of HIV-1 infection. Over 40,000 samples will be analyzed using the Illumina 660K chip. The WTCCC3 will utilize the 6,000 control genotypes generated by the WTCCC2. | gene, genomic, genetics, microarray, genome-wide association study, snp, genome-wide association, blood, dna, genotype, variation, genome, sequence variant, copy number variation, genetic variation, phenotype, disease |
is related to: Psychiatric Genomics Consortium has parent organization: Wellcome Trust Sanger Institute; Hinxton; United Kingdom |
Bipolar disorder, Coronary artery disease, Crohn's disease, Rheumatoid arthritis, Type 1 diabetes, Type 2 diabetes, Hypertension, Control, Multiple sclerosis, Breast cancer, Ankylosing spondylitis, Autoimmune thyroid disease, Malaria, Tuberculosis, Inflammatory bowel disease, Barrett's esophagus, Esophageal adenocarcinoma, Glaucoma, Ischemic stroke, Pre-eclampsia, Parkinson's disease, Psychosis endophenotypes, Psoriasis, Schizophrenia, Ulcerative colitis, Visceral leishmaniasis, Primary biliary cirrhosis, Anorexia nervosa, Human immunodeficiency virus, Renal transplant dysfunction, Diabetes | Wellcome Trust ; Bill and Melinda Gates Foundation ; Wellcome Trust Sanger Institute; Hinxton; United Kingdom |
PMID:17554300 | Access to summary data and individual-level genotype data is available by application to the Wellcome Trust Case Control Consortium Data Access Committee. Access to data will be granted to qualified investigators for appropriate use. | nif-0000-10551 | SCR_001973 | Wellcome Trust Case-Control Consortium (WTCCC) | 2026-08-01 12:01:40 | 213 | ||||
|
Alkermes Resource Report Resource Website |
Alkermes (RRID:SCR_010497) | ALKS | commercial organization | A biopharmaceutical company that focuses on central nervous system (CNS) diseases. The company is the result of a merger between Alkermes, Inc. and Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Elan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts and manufacturing facilities in Athlone, Ireland; Gainesville, Georgia; and Wilmington, Ohio. Alkermes has more than 20 commercial drug products and candidates that address serious and chronic diseases such as addiction, schizophrenia, diabetes and depression. Among these, five products are primary to the company: risperidone Long-Acting Injection (Risperdal Consta) for schizophrenia and bipolar 1 disorder, paliperidone palmitate (Invega Sustenna in the U.S., Xeplion in Europe) for schizophrenia, 4-aminopyridine (Ampyra in the U.S., Fampyra in Europe) to improve walking in patients with multiple sclerosis, naltrexone for extended-release injectable suspension (Vivitrol) for alcohol and opioid dependence, and exenatide extended-release for injectable suspension (Bydureon) for the treatment of type 2 diabetes. Bydureon is a once-weekly, long-acting form of the drug exenatide (Byetta) and was developed through a partnership between Amylin, Alkermes and Eli Lilly. It is approved in Europe and the U.S. (Wikipedia) | central nervous system, disease, biopharmaceutical company, drug | Central nervous system disease, Addiction, Schizophrenia, Diabetes, Depressive Disorder, Bipolar Disorder, Multiple Sclerosis, Alcohol dependence, Opioid dependence, Type 1 diabetes, Type 2 diabetes | ISNI: 0000 0004 0384 2510, nlx_158068, grid.472773.2, Wikidata: Q4727688 | https://ror.org/05sa44m96 | SCR_010497 | Alkermes plc | 2026-08-01 12:04:14 | 0 | |||||||
|
George Institute for Global Health Resource Report Resource Website 1+ mentions |
George Institute for Global Health (RRID:SCR_011212) | George Institute | institution | An independent medical research institute dedicated to improving global health that conducts high impact research that targets preventable illnesses and injuries that are the leading causes of death and disability worldwide, including heart and kidney disease, stroke, diabetes, mental illness, falls and traffic crashes. (Adapted from Wikipedia) | is related to: Kidney Health Initiative | Heart disease, Kidney disease, Stroke, Diabetes, Mental illness, Fall, Traffic crash | nlx_158485, grid.452860.d | https://ror.org/05e1zqb39 | SCR_011212 | The George Institute for Global Health | 2026-08-01 12:04:21 | 2 | |||||||
|
NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases Resource Report Resource Website 100+ mentions |
NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases (RRID:SCR_012895) | NIDDK | government granting agency | Center with mission to conduct and support medical research and research training and to disseminate science-based information on diabetes and other endocrine and metabolic diseases. The NIDDK supports a wide range of medical research through grants to universities and other medical research institutions across the country. | diabetes, metabolic disease, digestive, kidney, endocrine, medical research |
recommends: Cell Image Library (CIL) recommends: Biological General Repository for Interaction Datasets (BioGRID) recommends: NIDDK Central Repository recommends: Accelerating Medicines Partnership Type 2 Diabetes Knowledge Portal (AMP-T2D) recommends: Metabolomics Workbench recommends: PeptideAtlas recommends: Network Data Exchange (NDEx) recommends: Mouse Genome Informatics (MGI) recommends: Zebrafish Information Network (ZFIN) recommends: FlyBase recommends: Database of Interacting Proteins (DIP) recommends: WormBase recommends: PhysioNet recommends: Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) recommends: UniProt recommends: dbSNP recommends: DNA DataBank of Japan (DDBJ) recommends: European Nucleotide Archive (ENA) recommends: dbVar recommends: ClinicalTrials.gov recommends: European Variation Archive (EVA) recommends: MGnify recommends: Analysis, Visualization, and Informatics Lab-space (AnVIL) recommends: GenBank recommends: Gene Expression Omnibus (GEO) recommends: miRBase recommends: Database of Genomic Variants Archive (DGVa) recommends: Crystallography Open Database (COD) recommends: Coherent X-Ray Imaging Data Bank (CXIDB) recommends: Biological Magnetic Resonance Data Bank (BMRB) recommends: Worldwide Protein Data Bank (wwPDB) recommends: EMDataResource.org recommends: NCBI Assembly Archive Viewer recommends: Cambridge Crystallographic Data Centre (CCDC) recommends: Inorganic Crystal Structure Database (ICSD) recommends: Structural Biology Grid recommends: ArrayExpress recommends: GenomeRNAi recommends: NCBI database of Genotypes and Phenotypes (dbGap) recommends: Protein Circular Dichroism Data Bank (PCDDB) recommends: Electron Microscopy Data Bank at PDBe (MSD-EBI) recommends: PDBe - Protein Data Bank in Europe recommends: PubChem BioAssay recommends: Japanese Genotype-phenotype Archive (JGA) recommends: ProteomeXchange recommends: IntAct recommends: European Genome phenome Archive recommends: MetaboLights recommends: PubChem Substance recommends: The Immunology Database and Analysis Portal (ImmPort) recommends: STRENDA recommends: Kinetic Models of Biological Systems (KiMoSys) recommends: FLOWRepository recommends: Mass spectrometry Interactive Virtual Environment (MassIVE) recommends: Global Proteome Machine Database (GPM DB) recommends: Cancer Imaging Archive (TCIA) recommends: German Neuroinformatics Node (G-Node) recommends: 1000 Functional Connectomes Project recommends: ChEMBL recommends: Image Data Resource (IDR) recommends: SICAS Medical Image Repository recommends: ZENODO recommends: Dataverse Network Project recommends: NeuroMorpho.Org recommends: Mendeley Data recommends: NIMH Data Archive recommends: NIH Figshare Archive recommends: FigShare recommends: National Addiction and HIV Data Archive Program (NAHDAP) recommends: Dryad Digital Repository recommends: Open Science Framework recommends: OpenNeuro recommends: SPARC Portal lists: Mutant Mouse Resource and Research Center lists: NIDDK Research Resources is affiliated with: Cystic Fibrosis Research and Translation Centers is affiliated with: Nutrition and Obesity Research Centers is affiliated with: O'Brien Urology Centers is affiliated with: Hematology Centers is affiliated with: Polycystic Kidney Disease Research and Translation Centers is affiliated with: O'Brien Kidney Centers is affiliated with: Diabetes Research Centers is affiliated with: Digestive Disease Centers is affiliated with: Centers for Diabetes Translation Research is affiliated with: Pediatric Centers of Excellence in Nephrology is affiliated with: Focal Segmental Glomerulosclerosis in Children and Young Adults Interventional Study is related to: Bridging Interventional Development Gaps is related to: Polycystic Kidney Disease Research Resource Consortium has parent organization: National Institutes of Health is parent organization of: MTOPS Prostate Samples Analysis Consortium is parent organization of: Symptom Score for Benign Prostatic Hyperplasia is parent organization of: Type 1 Diabetes - Rapid Access to Intervention Development is parent organization of: National Diabetes Education Program is parent organization of: Family Investigation of Nephropathy of Diabetes is parent organization of: Frequent Hemodialysis Network Daily Trial is parent organization of: HemBase is parent organization of: NIDDK- National Institute of Diabetes and Digestive and Kidney Diseases Obesity Resources is parent organization of: dkCOIN is parent organization of: National Kidney Disease Education Program is parent organization of: Network of Minority Health Research Investigators is parent organization of: National Endocrine and Metabolic Diseases Information Service is parent organization of: National Diabetes Information Clearinghouse is parent organization of: National Digestive Diseases Information Clearinghouse is parent organization of: National Hematologic Diseases Information Service is parent organization of: National Kidney and Urologic Diseases Information Clearinghouse is parent organization of: Type 1 Diabetes Preclinical Testing Program is parent organization of: Frequent Hemodialysis Network Nocturnal Trial is parent organization of: Boston Area Community Health Survey is parent organization of: Minimally Invasive Surgical Therapies Treatment Consortium for Benign Prostatic Hyperplasia is parent organization of: Focal Segmental Glomerulosclerosis in Children and Young Adults Interventional Study |
Type 1 diabetes, Type 2 diabetes, Diabetes, Digestive disease, Kidney disease, Endocrine disease, Obesity, Blood disease, Liver disease, Urologic disease | nlx_inv_1005102 | SCR_012895 | National Institute of Diabetes and Digestive and Kidney Diseases | 2026-08-01 12:04:41 | 140 | |||||||
|
Genetics of Kidneys in Diabetes Resource Report Resource Website |
Genetics of Kidneys in Diabetes (RRID:SCR_000133) | GoKinD, Go KinD | biomaterial supply resource, material resource | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on July 31,2025. Collect, store, and distribute genetic samples from cases and controls of type 1 diabetes and diabetic nephropathy for investigator-driven research into the genetic basis of diabetic nephropathy. As the risk of kidney complications in type 1 diabetes appears to have a considerable genetic component, this study assembled a large data resource for researchers attempting to identify causative genetic variants. The types of data collected allowed traditional case-control testing, a rapid and often powerful approach, and family-based analysis, a robust approach that is not influenced by population substructure. | clinical, genetics, genetic variant, gene, data set |
is listed by: One Mind Biospecimen Bank Listing is listed by: NIDDK Information Network (dkNET) has parent organization: George Washington University; Washington D.C.; USA |
Type 1 diabetes, Diabetes, Diabetic nephropathy, Kidney disease | JDRF ; NIH |
PMID:16775037 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_152764 | http://www.gokind.org/access | SCR_000133 | Genetics of Kidneys in Diabetes (GoKinD) Study, Genetics of Kidneys in Diabetes Study | 2026-08-01 12:10:42 | 0 | |||
|
Living Biobank Resource Report Resource Website |
Living Biobank (RRID:SCR_001510) | Living Biobank | biomaterial supply resource, material resource | Provides investigators with the opportunity to obtain on-demand biological samples from selected individuals that TrialNet has developed through the longitudinal monitoring of individuals at risk for the development of type 1 diabetes within the Natural History study. Exploratory research is encouraged under this initiative. Studies must use TrialNet screened subjects, and cannot interfere with ongoing clinical trials or studies. Investigators can select the clinical characteristics needed for their study as well as the sample type and collection frequency. Although many Living Biobank studies may be implemented through cost-sharing with the TrialNet network, special sample collections and visits outside of the normal visit schedules will incur additional costs which should be covered by the approved applicant. In addition, some studies may require effort from the TrialNet coordinating center, with costs covered by the approved ancillary study. Living biobank studies will be evaluated with careful consideration for their potential impact on the objectives and performance of the TrialNet Natural History study. To protect the interests of TrialNet, each living biobank study must be reviewed and approved by the Ancillary Studies Committee before its initiation. All approved living biobank studies will be reviewed yearly to evaluate their progress, and impact on TrialNet as a whole. TrialNet welcomes the submission of living biobank studies as an adjunct to ongoing protocols. | whole blood, serum, plasma, dna, rna, peripheral blood mononuclear cell, blood |
is listed by: One Mind Biospecimen Bank Listing has parent organization: Type 1 Diabetes TrialNet |
Type 1 diaberes, Diabetes | Free, Freely available | nlx_152813 | SCR_001510 | TrialNet Living Biobank | 2026-08-01 12:10:36 | 0 | ||||||
|
Nuclear Receptor Signaling Atlas Resource Report Resource Website 100+ mentions |
Nuclear Receptor Signaling Atlas (RRID:SCR_003287) | NURSA | biomaterial supply resource, material resource | THIS RESOURCE IS NO LONGER IN SERVICE.Documented on February 25, 2022.Software tool as knowledge environment resource that accrues, develops, and communicates information that advances understanding of structure, function, and role in disease of nuclear receptors (NRs) and coregulators. It specifically seeks to elucidate roles played by NRs and coregulators in metabolism and development of metabolic disorders. Includes large validated data sets, access to reagents, new findings, library of annotated prior publications in field, and journal covering reviews and techniques.As of March 20, 2020, NURSA is succeeded by the Signaling Pathways Project (SPP). | nuclear receptor, coregulator, metabolism, metabolic disorder, type 2 diabetes, obesity, osteoporosis, lipid dysregulation, cardiovascular disease, oncology, regenerative medicine, environmental agent, genomics, proteomics, reagent, ligand, microarray, gene expression, data set, data analysis service, nuclear receptor signaling, signaling, high through put screening, receptor, ligand, journal, molecule, affinity purification, q-pcr, chip-chip, animal model, antibody, cell line, primer, transcriptomine, clinical trial, disease, drug, data set |
is used by: NIF Data Federation is used by: NIDDK Information Network (dkNET) is recommended by: National Library of Medicine lists: NURSA Transcriptomine lists: STRING lists: Nuclear Receptor Cistrome is listed by: NIH Data Sharing Repositories is listed by: NIDDK Research Resources is listed by: NIDDK Information Network (dkNET) is related to: dkCOIN is related to: Integrated Manually Extracted Annotation has parent organization: Baylor College of Medicine; Houston; Texas |
Metabolic disorder, Type 2 diabetes mellitus, Obesity, Osteoporosis, Lipid dysregulation, Cardiovascular disease, Diabetes, Cancer | NHLBI ; NIEHS ; NICHD ; NIDDK DK097748 |
DOI:10.1101/401729 | Free, Freely available | nif-0000-03208 | https://dknet.org/about/NURSA_Archive | http://www.nursa.org | SCR_003287 | NURSA - Nuclear Receptor Signaling Atlas, NURSA - The Nuclear Receptor Signaling Atlas | 2026-08-01 12:10:45 | 135 | ||
|
National Center for Integrative Biomedical Informatics Resource Report Resource Website 1+ mentions |
National Center for Integrative Biomedical Informatics (RRID:SCR_001538) | organization portal, data or information resource, portal | The Center develops conceptual models, computational infrastructure, an integrated knowledge repository, and query and analysis tools that enable scientists to effectively access and integrate the wealth of biological data. The National Center for Integrative Biomedical Informatics (NCIBI) was founded in October 2005 and is one of seven National Centers for Biomedical Computing (NCBC) in the NIH Roadmap. NCIBI is based at the University of Michigan as a part of the Center for Computational Medicine and Biology (CCMB). NCIBI is composed of biomedical researchers, computational biologists, computer scientists, developers and human-computer interaction specialists organized into seven major core functions. They work in interdisciplinary teams to collectively develop tools that are not only computationally powerful but also biologically relevant and meaningful. The four initial Driving Biological Projects (prostate cancer progression, Type 1 and type 2 diabetes and bipolar disorder) provide the nucleation point from which tool development is informed, launched, and tested. In addition to testing tools for function, a separate team is dedicated to testing usability and user interaction that is a unique feature of this Center. Once tools are developed and validated the goal of the Center is to share and disseminate data and software throughout the research community both internally and externally. This is achieved through various mechanisms such as training videos, tutorials, and demonstrations and presentations at national and international scientific conferences. NCIBI is supported by NIH Grant # U54-DA021519. | analysis tools, bipolar disorder, code, computational infrastructure, conceptual models, data, diabetes, knowledge repository, presentations, prostate cancer, query tools, seminar material, tool development, tutorials, videos, model |
is listed by: 3DVC is related to: Biological Concept Diagram Editor is related to: Gene Interaction Extraction from the Literature is related to: National Centers for Biomedical Computing has parent organization: University of Michigan; Ann Arbor; USA is parent organization of: Substructure Index-based Approximate Graph Alignment is parent organization of: miniTUBA is parent organization of: Michigan Molecular Interactions is parent organization of: Cell Line Knowledge Base is parent organization of: HubMed is parent organization of: MiMI Plugin for Cytoscape |
Type 1 diabetes, Type 2 diabetes, Diabetes, Cancer, Bipolar disorder | PMID:22101971 | Free, Freely available | nif-0000-09660 | http://portal.ncibi.org/gateway/ | SCR_001538 | NCIBI | 2026-08-02 09:03:04 | 1 | |||||
|
La Jolla Institute for Immunology Resource Report Resource Website |
La Jolla Institute for Immunology (RRID:SCR_014837) | LJI, | organization portal, data or information resource, portal | Non profit collaborative research organization located in La Jolla, California, UCSD Research Park. Institute researches immunology and immune system diseases to pinpoint specific genes involved, accelerate progress toward development of new treatments and vaccines to prevent and cure type 1 diabetes, cancer and infectious disease. Developer of Immune Epitope Database (IEDB). Provides core facilities with access to equipment, technologies, training and expertise to support innovative research. | Immunology, vaccine, infectious disease, immune system, Immune Epitope Database, sequencing, high throughput, bioinformatics |
is related to: Coronavirus Immunotherapy Consortium is parent organization of: Database of Immune Cell Epigenomes is parent organization of: La Jolla Institute for Immunology Next Generation Sequencing Core Facility is organization facet of: Immune Epitope Database and Analysis Resource (IEDB) |
Type 1 diabetes, Diabetes, Allergy, Alzheimer's disease, Asthma, Atherosclerosis, Atopic dermatitis, Eczema, Autoimmune disease, Cancer, COVID-19, Dengue, Ebola, Fibrosis, Food allergies, HIV, Imflammatory bowel disease, Japanese encephalitis, Lassa fever, Lung cancer, Multiple sclerosis, Nipah, Parkinson's disease, Pneumonia | SCR_014837 | LJI, la jolla, Institute for immunology, La Jolla Institute for Allergy and Immunology | 2026-08-02 09:07:04 | 0 | ||||||||
|
Corengi Resource Report Resource Website |
Corengi (RRID:SCR_003942) | community building portal, service resource, data or information resource, portal | A comprehensive, free, and interactive platform to help individuals discover more about clinical trials that may be appropriate for them for a variety of diseases. The platform allows stakeholders within the clinical trials community (investigators, site personnel, sponsors, and disease advocates) to engage with potential enrollees and educate them about specific clinical trials. They have identified some of the most commonly used criteria for the clinical trials in each disease. Using these criteria, they developed a questionnaire for a single disease. Then, looking at just those questions, they can start to get a sense of which clinical trials might be appropriate for a particular person which is a helpful to start to narrow down the list of potentially appropriate trials. All clinical trials that are posted on www.clinicaltrials.gov for the diseases that Corengi covers will be on the website. | clinical trial |
uses: ClinicalTrials.gov is related to: Patients to Trials Consortium |
Diabetes | Free | nlx_158330 | SCR_003942 | Corengi Inc., Clinical Options Research Engine | 2026-08-03 09:32:19 | 0 | |||||||
|
DanStem Resource Report Resource Website 1+ mentions |
DanStem (RRID:SCR_004021) | DanStem | topical portal, data or information resource, portal | Center consisting of 9 research groups who all address basic questions in stem cell and developmental biology with the overall aim of developing new stem cell-based therapeutic approaches for diabetes and cancer. DanStem comprises two sections: * The Novo Nordisk Foundation Section for Basic Stem Cell Biology (BasicStem) * The Section for Strategic Translational Stem Cell Research and Therapy (TransStem) DanStem was established as a result of a series of international recruitments coupled with internationally recognized research groups focused on insulin producing beta cells and cancer research already located at the University of Copenhagen. They all have well-established, international collaborations and actively participate in several international scientific consortia. DanStem is also active in training undergraduates, PhD students and postdocs. | stem cell, beta cell development, beta cell, insulin |
is related to: Beta Cell Biology Consortium has parent organization: University of Copenhagen; Copenhagen; Denmark |
Diabetes, Cancer | Novo Nordisk Foundation ; Danish Council for Strategic Research |
nlx_158446 | SCR_004021 | The Danish Stem Cell Center, Danish Stem Cell Center, DanStem - The Center for Stem Cell Research, Danish Center for Stem Cell Research | 2026-08-03 09:32:36 | 4 | ||||||
|
McEwen Centre for Regenerative Medicine Resource Report Resource Website 1+ mentions |
McEwen Centre for Regenerative Medicine (RRID:SCR_004020) | McEwen Centre | organization portal, data or information resource, laboratory portal, portal | Center aiming to be a catalyst for regenerative medicine by facilitating collaboration, supporting research, and promoting awareness of the field. The center includes 15 scientists at five Toronto hospitals, as well as the University of Toronto, currently working to accelerate the development of more effective treatments for conditions such as heart disease, diabetes, respiratory disease and spinal cord injury. They collaborate with many other research institutions throughout North America, Europe and the Asia / Pacific region. The research is powered by a team of recent doctoral graduates recruited from around the world that are selected through a competitive process. They are a critical tool for supporting the work of McEwen Centre, allowing them to find medical breakthroughs faster. | regenerative medicine, stem cell, postdoctoral program resource | is related to: Beta Cell Biology Consortium | Heart disease, Diabetes, Respiratory disease, Spinal cord injury | philanthropic contributions ; research grants |
nlx_158445 | SCR_004020 | McEwen Center, McEwen Center for Regenerative Medicine | 2026-08-03 09:32:21 | 1 | ||||||
|
BioGrid Australia Resource Report Resource Website 100+ mentions |
BioGrid Australia (RRID:SCR_006334) | BioGrid Australia | production service resource, data analysis service, service resource, database, analysis service resource, data or information resource | A federated data sharing platform and infrastructure that provides access to real-time clinical, imaging and biospecimen data across jurisdictions, institutions and diseases. The web-based platform provides a secure infrastructure that advances health research by linking privacy-protected and ethically approved data among a wide network of health collaborators. Access to de-identified health records data is granted to authorized researchers after an application process so patient privacy and intellectual property are protected. BioGrid Australia''s approved researchers are provided access to multiple institutional databases, via the BioGrid interface, preventing gaps in patient records and research analysis. This legal and ethical arrangement with participating collaborators allows BioGrid to connect data through a common platform where data governance and access is managed by a highly skilled team. Data governance, security and ethics are at the core of BioGrid''s federated data sharing platform that securely links patient level clinical, biospecimen, genetic and imaging data sets across multiple sites and diseases for the purpose of medical research. BioGrid''s infrastructure and data management strategies address the increasing need by authorized researchers to dynamically extract and analyze data from multiple sources whilst protecting patient privacy. BioGrid has the capability to link data with other datasets, produce tailored reports for auditing and reporting and provide statistical analysis tools to conduct more advanced research analysis. In the health sector, BioGrid is a trusted independent virtual real-time data repository. Government investment in BioGrid has facilitated a combination of technology, collaboration and ethics approval processes for data sharing that exist nowhere else in the world. | endocrinology, neuroscience, imaging, medicine, oncology, population, cancer, cystic fibrosis, diabetes, pet, mri, clinical, respiratory, health, epilepsy, neuropsychiatry, data sharing, FASEB list | Cancer, Diabetes, Epilepsy, Cystic fibrosis, Respiratory disease, Multiple Sclerosis, Stroke, Bone density | Closed; Authorized researchers only. | nlx_152036, r3d100012476 | https://doi.org/10.17616/R3921N | http://www.biogrid.org.au/wps/portal | SCR_006334 | BioGrid Australia Limited | 2026-08-03 09:33:05 | 294 | |||||
|
Johns Hopkins Point of Care Guides Resource Report Resource Website 1+ mentions |
Johns Hopkins Point of Care Guides (RRID:SCR_006314) | Johns Hopkins POC-IT Guides | mobile app, database, software application, data or information resource, software resource | Authoritative, need-to-know information from Johns Hopkins available for mobile devices and the web. Guides provide up to date information and break down details of diagnosis, drug indications, dosing, pharmacokinetics, side effects and interactions, pathogens, management, and vaccines into frequently-updated, quick-read entries. Available for infectious disease (ABX), diabetes, and HIV. | point of care, antibiotic, pathogen, infectious disease, drug, clinical test, management, complication, medication, clinical, infection, resistance | is related to: ABX Guide | Diabetes, Infectious disease, HIV | Available for purchase | nlx_151999 | SCR_006314 | Johns Hopkins Medicine POC-IT Guides, Johns Hopkins Guides: Antibiotic HIV and Diabetes Guides, POC-IT Guides | 2026-08-03 09:32:58 | 2 | ||||||
|
Autoimmunity Centers of Excellence Resource Report Resource Website |
Autoimmunity Centers of Excellence (RRID:SCR_006510) | ACE | portal, disease-related portal, resource, topical portal, research forum portal, data or information resource | Nine centers that conduct clinical trials and basic research on new immune-based therapies for autoimmune diseases. This program enhances interactions between scientists and clinicians in order to accelerate the translation of research findings into medical applications. By promoting better coordination and communication, and enabling limited resources to be pooled, ACEs is one of NIAID''''s primary vehicles for both expanding our knowledge and improving our ability to effectively prevent and treat autoimmune diseases. This coordinated approach incorporates key recommendations of the NIH Autoimmune Diseases Research Plan and will ensure progress in identifying new and highly effective therapies for autoimmune diseases. ACEs is advancing the search for effective treatments through: * Diverse Autoimmunity Expertise Medical researchers at ACEs include rheumatologists, neurologists, gastroenterologists, and endocrinologists who are among the elite in their respective fields. * Strong Mechanistic Foundation ACEs augment each clinical trial with extensive basic studies designed to enhance understanding of the mechanisms responsible for tolerance initiation, maintenance, or loss, including the role of cytokines, regulatory T cells, and accessory cells, to name a few. * Streamlined Patient Recruitment The cooperative nature of ACEs helps scientists recruit patients from distinct geographical areas. The rigorous clinical and basic science approach of ACEs helps maintain a high level of treatment and analysis, enabling informative comparisons between patient groups. | immune system, infection, clinical trial, clinical, basic research |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources |
Type 1 diabetes, Diabetes, Autoimmune disease, Systematic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome, Multiple sclerosis, Chronic inflammatory bowel disease, Pemphigus vulgaris, Scleroderma | NIAID ; NIDDK ; NIH Office of Research on Womens Health |
nlx_152751 | SCR_006510 | 2026-08-03 09:33:09 | 0 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.